Equities

Zhejiang Medicine Co Ltd

600216:SHH

Zhejiang Medicine Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)17.89
  • Today's Change-0.05 / -0.28%
  • Shares traded41.76m
  • 1 Year change+62.64%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,7881,8852,226
Total Receivables, Net1,6851,6751,872
Total Inventory2,0111,9951,873
Prepaid expenses11710064
Other current assets, total0.190.17--
Total current assets5,6015,6556,035
Property, plant & equipment, net6,0665,6735,422
Goodwill, net192836
Intangibles, net744748729
Long term investments261242226
Note receivable - long term------
Other long term assets------
Total assets12,78012,43312,532
LIABILITIES
Accounts payable1,1301,0291,389
Accrued expenses259271293
Notes payable/short-term debt22891274
Current portion long-term debt/capital leases370550450
Other current liabilities, total491525619
Total current liabilities2,4782,4653,025
Total long term debt231201251
Total debt829842975
Deferred income tax--2.4721
Minority interest356450403
Other liabilities, total845453
Total liabilities3,1493,1733,753
SHAREHOLDERS EQUITY
Common stock965965965
Additional paid-in capital2,0051,9411,692
Retained earnings (accumulated deficit)6,6826,4176,195
Treasury stock - common(28)(58)(60)
Unrealized gain (loss)------
Other equity, total5.77(5.27)(14)
Total equity9,6319,2608,779
Total liabilities & shareholders' equity12,78012,43312,532
Total common shares outstanding962958958
Treasury shares - common primary issue3.346.836.83
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.